Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 404
  • Home
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2019  |  Volume : 5  |  Issue : 2  |  Page : 100-104

A novel treatment option for patients suffering from migraine: Erenumab


1 Department of Cardiothoracic and Vascular Surgery, SMS Medical College and Hospital, Jaipur, Rajasthan, India
2 Department of Pharmaology, SMS Medical College and Hospital, Jaipur, Rajasthan, India
3 Department of Anatomy, SMS Medical College and Hospital, Jaipur, Rajasthan, India
4 Department of Medicine, SMS Medical College and Hospital, Jaipur, Rajasthan, India

Correspondence Address:
Dr. Neha Sharma
Department of Pharmaology, SMS Medical College, Jaipur, Rajasthan
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJAM.IJAM_42_18

Rights and Permissions

Migraine is one of the common disabling neurological disorders. It is conventionally treated by antihypertensives, antidepressants, and antiepileptics for prophylaxis. In spite of all these treatment options available, physicians were always in search of an ideal drug molecule with more target-specific drug action with lesser side effects and which may improve patient compliance. This exhaustive search led to the discovery of a new molecule in the pathophysiology of migraine that is calcitonin gene-related peptide (CGRP) and which in turn led to discovery of specific CGRP antagonists such as gepants and monoclonal antibodies such as erenumab. A systematic literature search was carried out on the internet using databases such as PubMed, Cochrane Reviews, Google Scholar, and Wikipedia using keywords such as migraine, erenumab, and CGRP receptor. Detailed information about pathophysiology of migraine, CGRP, and erenumab was gathered. Erenumab is the first human monoclonal antibody approved by the Food and Drug Administration in May 2018. It is marketed under the trade name “Aimovig.” It acts as an antagonist of CGRP receptors, which plays a key role in the pathophysiology of migraine. In spite of being macromolecular human monoclonal antibodies, it has very few side effects as compared to gepants. Erenumab may offer promising role in the preventive treatment of episodic and chronic migraine. The present study describes the mechanism of action, efficacy, and side effects as documented in three completed clinical trial findings of erenumab. The following core competencies are addressed in this article: Medical knowledge, Patient care and procedural skills.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed197    
    Printed17    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal